Nanologica AB (NICA) AI Stock Analysis

• Market Cap: €114.86M
• Dividend Yield: N/A
• Average Volume (3M): 111.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: 186.74%
• EPS Growth: 73.17%
• Country: SE
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 88,357,230
• 10 Day Avg. Volume: 89,035
• 30 Day Avg. Volume: 111,941
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: kr1.50 ▲(19.05% Upside)

The overall stock score is primarily impacted by the company's financial performance challenges, including negative profitability and cash flow issues. Technical analysis provides a neutral outlook, while valuation metrics are weak due to negative earnings. The absence of earnings call insights and corporate events leaves these areas unaddressed.

Nanologica AB Business Overview & Revenue Model

Company Description

Nanologica AB (NICA) is a Swedish biotechnology company specializing in the development and commercialization of innovative nanoparticle-based technologies for drug delivery and diagnostics. The company focuses on the pharmaceutical and healthcare sectors, leveraging its proprietary nanoparticle platform to enhance the efficacy of existing therapies and improve patient outcomes. Nanologica's core products include advanced drug delivery systems and diagnostic solutions that utilize its unique nanoscale materials.

How the Company Makes Money

Nanologica AB generates revenue primarily through collaborations and partnerships with pharmaceutical companies for the development of its drug delivery systems. The company enters into licensing agreements and joint ventures that provide upfront payments, milestone payments based on developmental progress, and royalties on future sales of products that utilize its technology. Additionally, Nanologica may engage in contract research services, providing tailored solutions to clients in the healthcare sector. The company's strategic alliances with research institutions and industry players further enhance its market reach and contribute to its financial performance.

Nanologica AB Financial Statement Overview

Summary

Nanologica AB faces significant challenges with profitability and cash flow, despite some revenue growth. The balance sheet shows moderate leverage but is threatened by periodic negative equity. The company must improve revenue stability, cost management, and reduce debt to enhance financial health.

Income Statement

Nanologica AB has shown significant volatility in revenue, with fluctuating growth rates. The TTM (Trailing-Twelve-Months) revenue growth indicates improvement, but the company consistently reports negative net profit margins due to high operating costs, reflected in the negative EBIT and EBITDA margins. The company needs to stabilize its revenue growth and manage costs to improve profitability.

Balance Sheet

The company's balance sheet reveals a moderate debt-to-equity ratio with a relatively stable equity over the years. However, the company has negative stockholders' equity in some periods, indicating potential financial instability. The equity ratio is low, highlighting a reliance on liabilities to finance assets. Improving equity and reducing liabilities could strengthen the financial position.

Cash Flow

Nanologica AB experiences negative free cash flow, indicating challenges in generating sufficient cash from operations. Although the operating cash flow to net income ratio is relatively consistent, the company shows significant financing cash flow, suggesting reliance on external funding. Effective cash flow management is essential for improving liquidity and reducing dependence on external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.41M	14.54M	1.44M	1.55M	12.91M	16.14M
Gross Profit	2.02M	4.29M	-76.00K	3.23M	4.92M	14.99M
EBITDA	-38.12M	-45.17M	-62.12M	-38.36M	-31.13M	-13.05M
Net Income	-60.22M	-65.63M	-75.16M	-55.09M	-50.13M	-24.83M
Balance Sheet
Total Assets	112.61M	143.10M	77.43M	154.51M	98.32M	146.34M
Cash, Cash Equivalents and Short-Term Investments	26.38M	48.43M	10.05M	70.32M	11.70M	67.98M
Total Debt	6.73M	50.94M	666.00K	4.69M	9.79M	12.96M
Total Liabilities	61.01M	68.99M	79.33M	81.36M	46.72M	53.38M
Stockholders Equity	51.59M	74.11M	-1.90M	73.16M	51.60M	92.97M
Cash Flow
Free Cash Flow	-69.33M	-81.48M	-56.83M	-53.78M	-53.74M	-49.86M
Operating Cash Flow	-69.29M	-80.73M	-35.85M	-45.22M	-46.49M	-43.34M
Investing Cash Flow	-45.00K	-742.00K	-20.35M	-7.14M	-7.25M	-6.52M
Financing Cash Flow	81.34M	120.23M	-4.09M	111.70M	-1.64M	115.05M

Nanologica AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.26
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NICA, the sentiment is Negative. The current price of 1.26 is above the 20-day moving average (MA) of 1.25, above the 50-day MA of 1.25, and below the 200-day MA of 1.42, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 49.74 is Neutral, neither overbought nor oversold. The STOCH value of 19.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NICA.

Nanologica AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALZ	―	kr158.15M	―	-20.22%	―	-67.00%	23.63%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXTCL	―	kr100.70M	―	-52.45%	―	2.56%	52.76%
NICA	―	€114.86M	-2.28	-294.38%	―	186.74%	73.17%
BIOVIC.B	―	€160.49M	-0.80	-146.43%	―	31.03%	55.25%
SPAGO	―	kr69.47M	―	-106.95%	―	-48.15%	52.00%
BIOSGN	―	kr110.37M	―	-101.53%	―	―	65.16%

Nanologica AB Corporate Events

Nanologica AB Sees Sales Surge and Expands Market Reach in Q3 2025

Nanologica AB reported a significant increase in net sales for Q3 2025, reaching SEK 2,843 thousand, compared to SEK 611 thousand in the previous year. The company also reduced its operating loss and received several orders for its NLAB Saga® product, including a notable entry into the insulin market with a Chinese manufacturer, indicating a positive shift in market engagement and potential growth opportunities.

The most recent analyst rating on (SE:NICA) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.

Nanologica AB Secures SEK 1 Million Order in China for NLAB Saga®

Nanologica AB has secured an order worth approximately SEK 1 million for its silica-based purification media, NLAB Saga®, from a new distribution partner in China. This order marks a significant step in expanding their market presence in China, as the company aims to increase sales efforts and serve more customers efficiently. The order is expected to be delivered in the fourth quarter, highlighting the company’s stable production and strategic focus on the Chinese market.

The most recent analyst rating on (SE:NICA) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.

Nanologica AB Secures Additional SEK 2.7 Million Order from US Customer

Nanologica AB has secured an additional order worth approximately SEK 2.7 million from a US-based peptide drug manufacturer for its silica-based purification media, NLAB Saga®. This supplementary order follows an initial order placed in June and indicates the customer’s intent to evaluate the product for potential inclusion in their production processes. The order underscores Nanologica’s stable production capabilities and is expected to be delivered in the fourth quarter, potentially enhancing the company’s market positioning and stakeholder value.

The most recent analyst rating on (SE:NICA) stock is a Hold with a SEK1.00 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.

Nanologica AB Forms Nomination Committee for 2026 AGM

Nanologica AB has announced the formation of its nomination committee for the 2026 Annual General Meeting, consisting of representatives from its three largest shareholders. This committee, representing 53% of the voting rights, will propose key decisions for the AGM, including board elections and remuneration policies, which are crucial for guiding the company’s strategic direction and ensuring effective governance.

The most recent analyst rating on (SE:NICA) stock is a Hold with a SEK1.00 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.

Nanologica AB Expands into Chinese Insulin Market with New Order

Nanologica AB has entered the Chinese insulin market with a SEK 2 million order for its silica-based purification media, NLAB Saga®, from an insulin manufacturer. This marks the first evaluation of NLAB Saga® for insulin manufacturing in China, highlighting the company’s expanding market reach and potential to lower manufacturing costs for clients, thereby strengthening its industry position.

The most recent analyst rating on (SE:NICA) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.